BiotechTube

Letrozole

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopausal Women With Advanced Breast Cancer

Conditions

Postmenopausal Women With Advanced Breast Cancer

Trial Timeline

Jun 1, 2001 → Oct 1, 2006

NCT ID
NCT00237211

About Letrozole

Letrozole is a phase 2 stage product being developed by Chugai Pharmaceutical for Postmenopausal Women With Advanced Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00237211. Target conditions include Postmenopausal Women With Advanced Breast Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Postmenopausal Women With Advanced Breast Cancer were approved

Approved (20) Terminated (1) Active (0)
✅Teriparatide + Strontium ranelateEli LillyApproved
✅teriparatideEli LillyApproved
✅Teriparatide + RaloxifeneEli LillyApproved
✅teriparatide + aldrenodate + raloxifeneEli LillyApproved
✅teriparatide + raloxifene HCl + placeboEli LillyApproved
✅Teriparatide + Risedronate + Placebo + Calcium + Vitamin DEli LillyApproved
✅LetrozoleNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00237198Phase 2Completed
NCT00237211Phase 2Completed
NCT00247663Phase 2Completed

Competing Products

20 competing products in Postmenopausal Women With Advanced Breast Cancer

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
LetrozoleChugai PharmaceuticalPhase 2
35
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
22
LetrozoleChugai PharmaceuticalPhase 2
35
menatetranone + alfacalcidolEisaiPhase 3
40
teriparatide + raloxifene + placeboEli LillyPhase 3
40
Teriparatide + Strontium ranelateEli LillyApproved
43
teriparatideEli LillyApproved
43
LY333334 + PlaceboEli LillyPhase 1
29
Teriparatide + RaloxifeneEli LillyApproved
43
teriparatide + aldrenodate + raloxifeneEli LillyApproved
43
LAE102 SC + Placebo SC + LAE102 IV + Placebo IVEli LillyPhase 1
29
BlosozumabEli LillyPhase 1
29
BlosozumabEli LillyPhase 1
21
Arzoxifene + RaloxifeneEli LillyPhase 3
40
teriparatide + raloxifene HCl + placeboEli LillyApproved
43
Raloxifene HCL + Raloxifene HCL + PlaceboEli LillyPhase 3
40